IN2012DN02551A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02551A IN2012DN02551A IN2551DEN2012A IN2012DN02551A IN 2012DN02551 A IN2012DN02551 A IN 2012DN02551A IN 2551DEN2012 A IN2551DEN2012 A IN 2551DEN2012A IN 2012DN02551 A IN2012DN02551 A IN 2012DN02551A
- Authority
- IN
- India
- Prior art keywords
- group
- salt
- derivative
- disclosed
- formula
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 150000002989 phenols Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000003424 uricosuric effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009227402A JP5325065B2 (ja) | 2009-09-30 | 2009-09-30 | 新規フェノール誘導体 |
| PCT/JP2010/066925 WO2011040449A1 (ja) | 2009-09-30 | 2010-09-29 | 新規フェノール誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02551A true IN2012DN02551A (enExample) | 2015-08-28 |
Family
ID=43826265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2551DEN2012 IN2012DN02551A (enExample) | 2009-09-30 | 2010-09-29 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8367843B2 (enExample) |
| EP (1) | EP2484669B1 (enExample) |
| JP (1) | JP5325065B2 (enExample) |
| KR (1) | KR101647174B1 (enExample) |
| CN (1) | CN102639518B (enExample) |
| AU (1) | AU2010301675B2 (enExample) |
| BR (1) | BR112012007069B1 (enExample) |
| CA (1) | CA2775309C (enExample) |
| DK (1) | DK2484669T3 (enExample) |
| ES (1) | ES2549603T3 (enExample) |
| HU (1) | HUE026007T2 (enExample) |
| IL (1) | IL218519A (enExample) |
| IN (1) | IN2012DN02551A (enExample) |
| MX (1) | MX2012003392A (enExample) |
| MY (1) | MY160394A (enExample) |
| NZ (1) | NZ598582A (enExample) |
| PH (1) | PH12012500643A1 (enExample) |
| PL (1) | PL2484669T3 (enExample) |
| PT (1) | PT2484669E (enExample) |
| RU (1) | RU2536689C2 (enExample) |
| TW (1) | TWI461195B (enExample) |
| WO (1) | WO2011040449A1 (enExample) |
| ZA (1) | ZA201201895B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5851802B2 (ja) | 2011-03-30 | 2016-02-03 | 富士重工業株式会社 | 炭素繊維強化樹脂複合材用ドリル |
| WO2015191034A1 (en) * | 2014-06-09 | 2015-12-17 | Baylor College Of Medicine | Small molecule xanthine oxidase inhibitors and methods of use |
| WO2017038799A1 (ja) * | 2015-09-04 | 2017-03-09 | サントリーホールディングス株式会社 | ウレアーゼ活性阻害剤 |
| CA2998034C (en) * | 2015-09-10 | 2021-05-04 | Dongfang Shi | A group of compounds used for the treatment or prevention of hyperuricemia or gout |
| CN105675557B (zh) * | 2016-01-07 | 2019-01-25 | 济南大学 | 基于苯炔荧光试剂检测硫脲含量的新方法 |
| KR102610573B1 (ko) | 2016-07-18 | 2023-12-05 | 아쓰로시 테라퓨틱스, 인크. | 통풍 또는 고뇨산혈증과 관련된 증상의 치료 또는 예방을 위한 화합물, 조성물 및 방법 |
| SG11201909747WA (en) * | 2017-04-28 | 2019-11-28 | Fuji Yakuhin Co Ltd | Crystal form and salt of 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole |
| CN109928890B (zh) * | 2017-12-15 | 2021-11-09 | 重庆常捷医药有限公司 | 一种托伐普坦中间体2-甲基-4-n-(2-甲基苯甲酰)苯甲酸的制备方法 |
| BR112021010708A2 (pt) | 2018-12-06 | 2021-08-24 | Arthrosi Therapeutics, Inc. | Formas cristalinas de um composto para tratar ou prevenir gota ou hiperuricemia |
| AU2019392750B2 (en) | 2018-12-06 | 2025-07-10 | Arthrosi Therapeutics, Inc. | Methods for treating or preventing gout or hyperuricemia |
| CA3159300A1 (en) * | 2019-12-09 | 2021-06-17 | Tadashi Inoue | Solid pharmaceutical preparation |
| CN111662247A (zh) * | 2020-07-17 | 2020-09-15 | 苏州明锐医药科技有限公司 | 一种多替诺德的合成方法 |
| CN111675675A (zh) * | 2020-07-17 | 2020-09-18 | 苏州明锐医药科技有限公司 | 多替诺德的制备方法 |
| CN112430221B (zh) * | 2020-11-20 | 2023-06-23 | 成都诺和晟泰生物科技有限公司 | 用于预防、治疗或减轻高尿酸血症或痛风的化合物及其应用 |
| WO2022169974A1 (en) | 2021-02-05 | 2022-08-11 | Nexys Therapeutics, Inc. | Inhibitors of urat1 and pharmaceutical uses thereof |
| CN114903879B (zh) * | 2022-06-23 | 2023-10-31 | 东北大学 | 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途 |
| CN115160314B (zh) * | 2022-07-28 | 2023-12-05 | 南方医科大学 | 杂环芳酰胺类化合物及其制备方法和应用 |
| WO2025085662A1 (en) | 2023-10-17 | 2025-04-24 | Vanderbilt University | Compounds for tocolytic use |
| CN118580197A (zh) * | 2023-11-16 | 2024-09-03 | 广东东阳光药业股份有限公司 | 一种多替诺雷制备方法及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3720683A (en) * | 1970-09-02 | 1973-03-13 | Squibb & Sons Inc | 2-phenyl-3-acylbenzothiazolines and their oxides |
| WO2005121112A1 (ja) | 2004-06-10 | 2005-12-22 | Torii Pharmaceutical Co., Ltd. | ６－ヒドロキシベンズブロマロン又はその塩からなる医薬組成物 |
| JP3988832B2 (ja) | 2004-11-29 | 2007-10-10 | 日本たばこ産業株式会社 | 窒素含有縮合環化合物及びその用途 |
| AR051780A1 (es) * | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos |
| EP1985297A1 (en) * | 2006-01-27 | 2008-10-29 | Japan Tobacco, Inc. | Carboxylic acid compound and use thereof |
| US20080305169A1 (en) * | 2006-05-26 | 2008-12-11 | Japan Tobacco Inc. | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds |
| US20080064871A1 (en) * | 2006-05-26 | 2008-03-13 | Japan Tobacco Inc. | Production Method of Nitrogen-Containing Fused Ring Compounds |
| WO2008062740A1 (fr) * | 2006-11-20 | 2008-05-29 | Japan Tobacco Inc. | Composé azoté à anneaux fusionnés et son utilisation |
-
2009
- 2009-09-30 JP JP2009227402A patent/JP5325065B2/ja active Active
-
2010
- 2010-09-29 KR KR1020127007939A patent/KR101647174B1/ko active Active
- 2010-09-29 CN CN201080042866.9A patent/CN102639518B/zh active Active
- 2010-09-29 HU HUE10820564A patent/HUE026007T2/en unknown
- 2010-09-29 PT PT108205642T patent/PT2484669E/pt unknown
- 2010-09-29 NZ NZ598582A patent/NZ598582A/xx unknown
- 2010-09-29 MY MYPI2012001060A patent/MY160394A/en unknown
- 2010-09-29 TW TW099132910A patent/TWI461195B/zh active
- 2010-09-29 CA CA2775309A patent/CA2775309C/en active Active
- 2010-09-29 PH PH1/2012/500643A patent/PH12012500643A1/en unknown
- 2010-09-29 PL PL10820564T patent/PL2484669T3/pl unknown
- 2010-09-29 RU RU2012117786/04A patent/RU2536689C2/ru active
- 2010-09-29 US US13/499,190 patent/US8367843B2/en active Active
- 2010-09-29 EP EP10820564.2A patent/EP2484669B1/en active Active
- 2010-09-29 BR BR112012007069-0A patent/BR112012007069B1/pt active IP Right Grant
- 2010-09-29 IN IN2551DEN2012 patent/IN2012DN02551A/en unknown
- 2010-09-29 DK DK10820564.2T patent/DK2484669T3/en active
- 2010-09-29 WO PCT/JP2010/066925 patent/WO2011040449A1/ja not_active Ceased
- 2010-09-29 ES ES10820564.2T patent/ES2549603T3/es active Active
- 2010-09-29 AU AU2010301675A patent/AU2010301675B2/en active Active
- 2010-09-29 MX MX2012003392A patent/MX2012003392A/es active IP Right Grant
-
2012
- 2012-03-07 IL IL218519A patent/IL218519A/en active IP Right Grant
- 2012-03-14 ZA ZA2012/01895A patent/ZA201201895B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02551A (enExample) | ||
| NZ600840A (en) | Indole compound and pharmaceutical use thereof | |
| AR065810A1 (es) | Derivados de isoindolina 4'-o-sustituidos,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer y en otros trastornos donde es necesario el control de la angiogenesis o la inhibicion de citoquinas, incluyendo tnf-alfa. | |
| SI1992618T1 (sl) | Policiklični derivat cinamida | |
| MX2011011136A (es) | Eteres diarilicos. | |
| PH12012500752A1 (en) | Benzimidazole-imidazole derivatives | |
| EP2209518A4 (en) | DISEASE DISAPPEARANCE HIGH FREQUENCY NERVE BLOCKADE | |
| IN2014MN02106A (enExample) | ||
| NZ593030A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| WO2009016460A8 (en) | Pyrazole compounds and their use as raf inhibitors | |
| MY151003A (en) | Stable pharmaceutical composition comprising a pyrimidine-sulfamide | |
| MX2014015158A (es) | Derivados de piridinona y piridazinona. | |
| MX2010006882A (es) | Derivado novedoso de catecol, composición farmaceutica que contiene el mismo, uso del derivado de catecol, y uso de la composición farmaceutica. | |
| MX2009005217A (es) | Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos. | |
| MX2010005824A (es) | Derivados de aminotiazol. | |
| ECSP088229A (es) | Derivados de pirazolona como inhibidores de 11-beta hsd1 | |
| PH12013500695A1 (en) | Pharmaceutical compositions containing a dgat1 inhibitor | |
| MX2010005714A (es) | Compuestos de piridina. | |
| GEP20125389B (en) | Substituted pyrazole and triazole compounds as ksp inhibitors | |
| MX2012006696A (es) | Derivados de 3, 4, 4a, 10b-tetrahidro-1h-tiopirano-[4, 3-c]-isoqunolina. | |
| MX2009003169A (es) | Derivados de sulfonamida. | |
| PH12012500992A1 (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
| EP2007372A4 (en) | Dialkyl-ABAGBEWIRKSTOFFE | |
| IN2015DN03869A (enExample) | ||
| UA105034C2 (uk) | Фармацевтична комбінація 5-фторурацилу і похідного 1,4-дигідропіридину та її застосування в лікуванні раку |